Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.60 |
| ▸ | PPARA | Q07869 | 15/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999069 | 0.90 | PPARD (0.58) | PPARDPPARAKDM4EPPARGEGFR | |
| SCHEMBL1385979 | 0.90 | PPARD (0.62) | PPARDPPARAKDM4EPPARGICMT | |
| SCHEMBL2000620 | 0.88 | PPARD (0.57) | PPARDPPARAKDM4EMEN1KMT2A | |
| SCHEMBL1998422 | 0.84 | PPARD (0.62) | PPARDPPARAKDM4EMEN1KMT2A | |
| SCHEMBL1995078 | 0.82 | PPARD (0.62) | PPARDPPARAKDM4EPPARG | |
| SCHEMBL2000709 | 0.82 | PPARD (0.57) | PPARDPPARAKDM4EPPARGICMT | |
| SCHEMBL2003148 | 0.81 | PPARD (0.57) | PPARDPPARAKDM4EMEN1KMT2A | |
| SCHEMBL2004739 | 0.81 | PPARD (0.54) | PPARDPPARAKDM4EPPARGALDH1A1 | |
| SCHEMBL2000807 | 0.81 | PPARD (0.58) | PPARDPPARAKDM4EPPARGALDH1A1 | |
| SCHEMBL2000619 | 0.79 | PPARD (0.58) | PPARDPPARAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885KDM4E 1373/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885KDM4E 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.